These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36837928)

  • 61. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 62. β-d-N
    Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A
    Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters.
    Abdelnabi R; Maes P; de Jonghe S; Weynand B; Neyts J
    Front Pharmacol; 2022; 13():1072202. PubMed ID: 36605401
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
    Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
    Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
    [TBL] [Abstract][Full Text] [Related]  

  • 65. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design.
    Shehzadi K; Yu M; Liang J
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139312
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.
    Reçber T; Timur SS; Erdoğan Kablan S; Yalçın F; Karabulut TC; Neslihan Gürsoy R; Eroğlu H; Kır S; Nemutlu E
    J Pharm Biomed Anal; 2022 May; 214():114693. PubMed ID: 35276385
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SARS-CoV-2 variant of concern type and biological sex affect efficacy of molnupiravir in dwarf hamster model of severe COVID-19.
    Lieber CM; Cox RM; Sourimant J; Wolf JD; Juergens K; Phung Q; Saindane MT; Natchus MG; Painter GR; Sakamoto K; Greninger AL; Plemper RK
    bioRxiv; 2022 Feb; ():. PubMed ID: 35169793
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Small-Molecule Antiviral β-d-
    Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
    J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification of FDA-approved drugs against SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) through computational virtual screening.
    Jade D; Alzahrani A; Critchley W; Ponnambalam S; Harrison MA
    Struct Chem; 2023; 34(3):1005-1019. PubMed ID: 36467260
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molnupiravir: From Hope to Epic Fail?
    Focosi D
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36423169
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice.
    Ullah I; Escudie F; Scandale I; Gilani Z; Gendron-Lepage G; Gaudette F; Mowbray C; Fraisse L; Bazin R; Finzi A; Mothes W; Kumar P; Chatelain E; Uchil PD
    bioRxiv; 2023 Jun; ():. PubMed ID: 37398307
    [TBL] [Abstract][Full Text] [Related]  

  • 72. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
    Atmar RL; Finch N
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.
    Bihorel S; Cao Y; Chawla A; Birger R; Maas BM; Gao W; Roepcke S; Sardella S; Humphrey R; Kondragunta S; Jayaraman B; Martinho M; Painter W; Painter G; Holman W; De Anda C; Brown ML; Johnson MG; Paschke A; Rizk ML; Stone JA
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1859-1871. PubMed ID: 37798914
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Why Molnupiravir Fails in Hospitalized Patients.
    Brown AN; Lang Y; Zhou J; Franco EJ; Hanrahan KC; Bulitta JB; Drusano GL
    mBio; 2022 Dec; 13(6):e0291622. PubMed ID: 36374076
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion.
    Chen TH; Tsai MJ; Chang CS; Xu L; Fu YS; Weng CF
    J Infect Public Health; 2023 Jan; 16(1):42-54. PubMed ID: 36470006
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.
    Iwamoto M; Duncan KE; Wickremasingha PK; Zhao T; Liberti MV; Lemoine L; Decaesteker T; Rottey S; Maas BM; Gillespie G; Stoch SA
    Clin Transl Sci; 2023 Oct; 16(10):1947-1956. PubMed ID: 37526305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.
    Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C
    Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Strong Dual Antipolymerase/Antiexonuclease Actions of Some Aminothiadiazole Antioxidants: A Promising
    Rabie AM; Eltayb WA
    Adv Redox Res; 2023 Jan; ():100064. PubMed ID: 36776420
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Molnupiravir Use Among Patients with COVID-19 in Real-World Settings: A Systematic Literature Review.
    Richmond DiBello J; Raziano VT; Liu X; Puenpatom A; Peebles K; Khan NF; Hill DD
    Infect Dis Ther; 2024 Jun; 13(6):1177-1198. PubMed ID: 38743192
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Tautomeric State of
    Bessi I; Stiller C; Schroeder T; Schäd B; Grüne M; Dietzsch J; Höbartner C
    ACS Cent Sci; 2024 May; 10(5):1084-1093. PubMed ID: 38799674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.